LCM
CCXI

Laurion Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Laurion Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-250,900
Closed -$4.29M – 773
2021
Q3 		$4.29M Buy
+250,900
New +$3.91M 0.02% 361

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Laurion Capital Management's CCXI Position: Q4 2021 in Review

Laurion Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q4 2021, closing a stake of 250,900 shares — an estimated $4.29M sold.

Laurion Capital Management first reported a position in CCXI in Q3 2021 and held it in 1 quarter. The position peaked at $4.29M in Q3 2021. 190 funds tracked by Wall St. Rank hold CCXI as of Q4 2021.

  • Laurion Capital Management reported no remaining ChemoCentryx, Inc. position as of Q4 2021 after selling out during the quarter.
  • Laurion Capital Management sold 250,900 ChemoCentryx, Inc. shares in Q4 2021, an estimated $4.29M.
  • Laurion Capital Management first reported a position in ChemoCentryx, Inc. in Q3 2021 and held it in 1 quarter.
  • Laurion Capital Management's ChemoCentryx, Inc. position peaked at $4.29M in Q3 2021.
  • 190 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2021.

Based on Laurion Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.